Your browser doesn't support javascript.
loading
Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu, María Fernanda; López Daneri, Gabriela A; Relloso, Silvia; Zarlenga, Leandro Jorge; Vinante, Mónica Alejandra; Mujica, María Teresa.
Afiliação
  • Landaburu MF; Centro de Micología, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina; Sanatorio Municipal Dr. Julio Méndez, Buenos Aires, Argentina.
  • López Daneri GA; Centro de Micología, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Relloso S; Centro de Micología, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Zarlenga LJ; Sanatorio Municipal Dr. Julio Méndez, Buenos Aires, Argentina.
  • Vinante MA; Sanatorio Municipal Dr. Julio Méndez, Buenos Aires, Argentina.
  • Mujica MT; Centro de Micología, Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. Electronic address: mtmujica@gmail.com.
Rev Argent Microbiol ; 52(1): 27-30, 2020.
Article em En | MEDLINE | ID: mdl-31262611
ABSTRACT
The yeast Saccharomyces cerevisiae var. boulardii is a biotherapeutic agent used for the prevention and treatment of several gastrointestinal diseases. We report a case of fungemia in a patient suffering from Clostridiumdifficile-associated diarrhea and treated with metronidazole and a probiotic containing S. cerevisiae var. boulardii. The yeasts isolated from the blood culture and capsules were identified by MALDI-TOF MS and API ID 32 C as S. cerevisiae, and showed the same appearance and color on CHROMAgar Candida. Treatment with fluconazole 400mg/day was initiated and the probiotic was stopped. The patient was discharged from hospital in good condition and was referred to a rehabilitation center. We suggest that the potential benefit of S. cerevisiae var. boulardii should be accurately evaluated, especially in elderly patients. Moreover, all physicians should be trained in the use of probiotic agents and enquire whether the use probiotics was included in the patients'medical histories.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Saccharomyces cerevisiae / Fungemia / Probióticos / Saccharomyces boulardii / Micoses Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Saccharomyces cerevisiae / Fungemia / Probióticos / Saccharomyces boulardii / Micoses Idioma: En Ano de publicação: 2020 Tipo de documento: Article